AbbVie Launches $70 Million Biologics Manufacturing Expansion in Worcester to Enhance R&D Capacity

AbbVie Begins Construction of $70 Million Biologics Manufacturing Expansion

AbbVie (NYSE: ABBV), a leading global biopharmaceutical company, has officially commenced construction on a significant expansion project valued at $70 million at its AbbVie Bioresearch Center (ABC) located in Worcester, Massachusetts. This initiative marks a crucial step in the company's ongoing commitment to strengthen its biologics manufacturing capabilities and enhance its research and development (R&D) operations within the United States.

The announced expansion is aligned with AbbVie's previously stated commitment to invest over $10 billion in U.S. operations. This ambitious financial investment is aimed at promoting innovation while expanding essential manufacturing capabilities. The Worcester facility serves as a center of excellence, particularly for the development and manufacturing of biologics targeting serious diseases in the fields of immunology and oncology.

As part of the expansion, additional manufacturing areas will be constructed, alongside a new three-story building that will house advanced laboratory, warehouse, and office spaces. This enhanced infrastructure is strategically designed to meet the increasing global demand for biologics and will facilitate the expedited transfer of specific oncology products from AbbVie's European facilities to the U.S. market.

Dr. Azita Saleki-Gerhardt, Executive Vice President and Chief Operations Officer at AbbVie, emphasized the importance of this investment by stating, "For more than three decades, ABC has been at the forefront of scientific innovation and biologics manufacturing. This investment will further expand AbbVie's biologics manufacturing capacity and position ABC to build upon its impressive track record of developing, manufacturing and launching next-generation complex biologic medicines that improve the lives of millions of patients worldwide."

AbbVie currently operates in all 50 states, along with Puerto Rico, and employs approximately 28,000 individuals in the United States, including over 2,000 in Massachusetts alone. The new expansion is anticipated to create numerous job opportunities at the ABC site, thereby contributing to AbbVie's extensive U.S. manufacturing footprint. Overall, the company's facilities support more than 6,000 American jobs across 11 different manufacturing locations.

In conclusion, AbbVie’s funding of $70 million into its Worcester facility signals a robust dedication to advancing biologics research and production in the U.S. Given the growing global demand for innovative treatment solutions, this development demonstrates AbbVie’s proactive approach in bolstering its capacity to meet patient needs while fostering local employment opportunities. The ongoing efforts to enhance R&D capabilities will also ensure that AbbVie remains competitive in an evolving healthcare landscape, particularly in the crucial therapeutic areas of immunology and oncology.

For further information about AbbVie and its initiatives, visit AbbVie and follow the company on social media platforms including LinkedIn, Facebook, Instagram, and YouTube.